Dominika Skwierawska

Ms. Dominika Skwierawska

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
DSDominika Skwierawska
Dominika Skwierawska
José Antonio López-ValverdeJosé Antonio López-Valverde
José Antonio López-Valverde
Marcin BalcerzykMarcin Balcerzyk
Marcin Balcerzyk
APAntonio Leal Plaza
Antonio Leal Plaza
Boron Neutron Capture Therapy (BNCT) is a promising binary disease-targeted therapy, as neutrons preferentially kill cells labeled with boron (10B), which makes it a precision medicine treatment modality that provides a therapeutic effect exclusively on patient-specific tumor spread. Contrary to what is usual in radiotherapy, BNCT proposes cell-tailored treatment planning rather than to the tumor mass. The success of BNCT depends mainly on the sufficient spatial biodistribution of 10B located around or within neoplastic cells to produce a high-dose gradient between the tumor and healthy tissue. However, it is not yet possible to precisely determine the concentration of 10B in a specific tissue in real-time using non-invasive methods. Critical issues remain to be resolved if BNCT is to become a valuable, minimally invasive, and efficient treatment. In addition, functional imaging technologies, such as PET, can be applied to determine biological information that can be used for the combined-modality radiotherapy protocol for each specific patient. Regardless, not only imaging methods but also proteomics and gene expression methods will facilitate BNCT becoming a modality of personalized medicine. This work provides an overview of the fundamental principles, recent advances, and future directions of BNCT as cell-targeted cancer therapy for personalized radiation treatment.

16 May 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
DSDominika Skwierawska
Dominika Skwierawska
José Antonio López-ValverdeJosé Antonio López-Valverde
José Antonio López-Valverde
Marcin BalcerzykMarcin Balcerzyk
Marcin Balcerzyk
APAntonio Leal Plaza
Antonio Leal Plaza
Boron Neutron Capture Therapy (BNCT) is a promising binary disease-targeted therapy, as neutrons preferentially kill cells labeled with boron (10B), which makes it a precision medicine treatment modality that provides a therapeutic effect exclusively on patient-specific tumor spread. Contrary to what is usual in radiotherapy, BNCT proposes cell-tailored treatment planning rather than to the tumor mass. The success of BNCT depends mainly on the sufficient spatial biodistribution of 10B located around or within neoplastic cells to produce a high-dose gradient between the tumor and healthy tissue. However, it is not yet possible to precisely determine the concentration of 10B in a specific tissue in real-time using noninvasive methods. Critical issues remain to be resolved if BNCT is to become a valuable, minimally invasive, and efficient treatment. Moreover, functional imaging technologies such as PET can be applied to determine biological information that can be used for the combined-modality radiotherapy protocol for each specific patient. Anyway, not only imaging methods but also proteomics and gene expression methods will facilitate BNCT becoming a modality of personalized medicine. This work provides an overview of the fundamental principles, recent advances, and future directions of BNCT as cell-targeted cancer therapy for personalized radiation treatment.

12 June 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
DBDimitrios Bounias
Dimitrios Bounias
TFTobit Führes
Tobit Führes
LBLuise Brock
Luise Brock
JGJohanna Graber
Johanna Graber
LKLorenz A. Kapsner
Lorenz A. Kapsner
SBSebastian Bickelhaupt
Sebastian Bickelhaupt
Prognosis for thoracic aortic aneurysms is significantly worse for women than men, with a higher mortality rate observed among female patients. The increasing use of magnetic resonance breast imaging (MRI) offers a unique opportunity for simultaneous detection of both breast cancer and thoracic aortic aneurysms. We retrospectively validate a fully-automated artificial neural network (ANN) pipeline on 5057 breast MRI examinations from public (Duke University Hospital/EA1141 trial) and in-house (Erlangen University Hospital) data. The ANN, benchmarked against 3D-ground-truth segmentations, clinical reports, and a multireader panel, demonstrates high technical robustness (dice/clDice 0.88-0.91/0.97-0.99) across different vendors and field strengths. The ANN improves aneurysm detection rates by 3.5-fold compared with routine clinical readings, highlighting its potential to improve early diagnosis and patient outcomes. Notably, a higher odds ratio (OR = 2.29, CI: [0.55,9.61]) for thoracic aortic aneurysms is observed in women with breast cancer or breast cancer history, suggesting potential further benefits from integrated simultaneous assessment for cancer and aortic aneurysms.

29 April 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
DSDominika Skwierawska
Dominika Skwierawska
FLFrederik Bernd Laun
Frederik Bernd Laun
EWEvelyn Wenkel
Evelyn Wenkel
LKLorenz A. Kapsner
Lorenz A. Kapsner
RJRolf Janka
Rolf Janka
SBSebastian Bickelhaupt
Sebastian Bickelhaupt
Several breast pathologies can affect the skin, and clinical pathways might differ significantly depending on the underlying diagnosis. This study investigates the feasibility of using diffusion-weighted imaging (DWI) to differentiate skin pathologies in breast MRIs. This retrospective study included 88 female patients who underwent diagnostic breast MRI (1.5 or 3T), including DWI. Skin areas were manually segmented, and the apparent diffusion coefficients (ADCs) were compared between different pathologies: inflammatory breast cancer (IBC; n = 5), benign skin inflammation (BSI; n = 11), Paget’s disease (PD; n = 3), and skin-involved breast cancer (SIBC; n = 11). Fifty-eight women had healthy skin (H; n = 58). The SIBC group had a significantly lower mean ADC than the BSI and IBC groups. These differences persisted for the first-order features of the ADC (mean, median, maximum, and minimum) only between the SIBC and BSI groups. The mean ADC did not differ significantly between the BSI and IBC groups. Quantitative DWI assessments demonstrated differences between various skin-affecting pathologies, but did not distinguish clearly between all of them. More extensive studies are needed to assess the utility of quantitative DWI in supplementing the diagnostic assessment of skin pathologies in breast imaging.

28 February 2025 in Investigative Radiology
Verified
Journal Article
Closed access
MBMaximilian Bachl
Maximilian Bachl
DSDominika Skwierawska
Dominika Skwierawska
DHDominique Hadler
Dominique Hadler
HSHannes Msc Schreiter
Hannes Msc Schreiter
MUMichael Uder
Michael Uder
SBSebastian Bickelhaupt
Sebastian Bickelhaupt
Objectives: Recent advances in high-performance gradient technology have enabled shorter echo times (TEs) for diffusion-weighted prostate MRI. Short TE may improve the conspicuity of the usually T2 hypointense lesions but may also influence the diagnostic performance of the apparent diffusion coefficient (ADC) due to a changed weighting of subcompartments, including prostate fluid and tissues. The purpose of this study was to evaluate the influence of TE on prostate diffusion-weighted images with respect to lesion conspicuity and diagnostic performance of the ADC. Materials and Methods: This institutional review board–approved prospective monocentric study included n = 55 (mean age 69 ± 9 years) patients undergoing clinically indicated prostate MRI on two 3 T MRI scanners with high-performance gradients. Diffusion-weighted imaging (DWI) was performed with an echo-planar sequence at 2 different TEs, 41 ms and 70 ms, with b-values of 50 s/mm2 and 800 s/mm2. Computed DWI was generated for a b-value of 1400 s/mm2. The lesion conspicuity and image quality were rated by 3 independent readers with a 5-point Likert scale and tested with the Wilcoxon rank sum test. Lesion ADCs were recorded, and their ability to detect significant lesions (Gleason score >6) was assessed with a receiver operator curve analysis. Results: Among the participants, n = 24 had clinically significant prostate cancer. The image quality at b = 1400 s/mm2 was rated significantly higher at TE = 41 ms than at TE = 70 ms (mean Likert score ± standard deviation for TE = 41 ms vs TE = 70 ms: R1: 4.06 ± 0.68 vs 3.02 ± 0.59; R2: 4.09 ± 0.82 vs 3.26 ± 0.67; R3: 4.16 ± 0.71 vs 3.18 ± 0.70; for all P’s < 0.001). The lesion conspicuity at b = 1400 s/mm2 was rated higher at TE = 41 ms than at TE = 70 ms (mean Likert score ± standard deviation for TE = 41 ms vs TE = 70 ms: R1: 4.55 ± 0.66 vs 4.46 ± 0.72, P = 0.17; R2: 4.64 ± 0.59 vs 4.53 ± 0.63, P = 0.03; R3: 4.53 ± 0.66 vs 4.28 ± 0.80, P = 0.01). However, the ADC-based area under the curve for lesion characterization decreased from 0.80 at TE = 70 ms to 0.70 at TE = 41 ms (P = 0.07). Conclusions: Shortening TE to 41 ms in prostate DWI increases lesion conspicuity on high b-value images; however, it negatively impacts the diagnostic performance of the ADC.

5 October 2026 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Open access
PDF file
AMAmeya Markale
Ameya Markale
LBLuise Brock
Luise Brock
IHIhor Horishnyi
Ihor Horishnyi
DSDominika Skwierawska
Dominika Skwierawska
TNTri‐Thien Nguyen
Tri‐Thien Nguyen
SBSebastian Bickelhaupt
Sebastian Bickelhaupt
Background: Diffusion‐weighted imaging (DWI) can support lesion detection and characterization in breast MRI. Therefore, DWI is increasingly being incorporated into breast MRI protocols to address some of the shortcomings of routine clinical breast MRI. However, especially high b value DWI can be prone to intensity artifacts that can affect diagnostic image assessment. Purpose: To detect hyper‐ and hypointense artifacts on high b value DWI ( b = 1500 s/mm 2 ) using deep learning, employing either a binary classification (artifact presence) or a multiclass classification (artifact intensity) approach on a slice‐wise dataset. Study Type: Retrospective. Study Population: 11,806 DWI slices were acquired from 156 examinations performed on female patients between 2022 and mid‐2023. For both hyper‐ and hypointense artifact classification, the slices were split into test, validation, and holdout test set with 8164/1806/1836 and 8164/1820/1822 slices in these sets respectively. Field Strength/Sequence: 3 T spin‐echo planar diffusion‐weighted sequence with b values: 50, 750, and 1500 s/mm 2 . Assessment: Three convolutional neural network (CNN) architectures (DenseNet121, ResNet18, and SEResNet50) were trained for binary classification of hyper‐ and hypointense artifacts on slice‐wise labeled data. The best performing model (DenseNet121) was applied to an independent holdout test set and further trained separately for multiclass classification. Statistical Tests: Performance of the networks was evaluated using accuracy, precision, recall, and areas under the receiver operating characteristic curve (AUROC) and under the precision recall curve (AUPRC). Radiologist evaluated bounding box positions on a 5‐point Likert‐like scale across 150 slices for validation and 200 slices for the holdout test set, derived from the network's Grad‐CAM heatmaps. Results: DenseNet121 achieved AUROCs of 0.91 and 0.95 for hyper‐ and hypointense artifact detection, respectively, and weighted AUROCs of 0.84 and 0.90 for multiclass classification on single‐slice high b value diffusion‐weighted images, achieving mean scores of 3.52 ± 0.81 for hyperintense artifacts and 3.62 ± 0.65 for hypointense artifacts. Data Conclusion: Hyper‐ and hypointense artifact detection in slice‐wise breast DWI MRI dataset ( b = 1500 s/mm 2 ) using CNNs, particularly DenseNet121, suggests potential reliability and requires further validation. Evidence Level: 3. Technical Efficacy: Stage 3.